These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19520196)

  • 1. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons.
    Chege GK; Thomas R; Shephard EG; Meyers A; Bourn W; Williamson C; Maclean J; Gray CM; Rybicki EP; Williamson AL
    Vaccine; 2009 Jul; 27(35):4857-66. PubMed ID: 19520196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
    Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
    Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
    Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.
    Chege GK; Burgers WA; Stutz H; Meyers AE; Chapman R; Kiravu A; Bunjun R; Shephard EG; Jacobs WR; Rybicki EP; Williamson AL
    J Virol; 2013 May; 87(9):5151-60. PubMed ID: 23449790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine.
    Chege GK; Shephard EG; Meyers A; van Harmelen J; Williamson C; Lynch A; Gray CM; Rybicki EP; Williamson AL
    J Gen Virol; 2008 Sep; 89(Pt 9):2214-2227. PubMed ID: 18753231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
    Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
    Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradermal and oral immunization with recombinant Mycobacterium bovis BCG expressing the simian immunodeficiency virus Gag protein induces long-lasting, antigen-specific immune responses in guinea pigs.
    Kawahara M; Matsuo K; Honda M
    Clin Immunol; 2006 Apr; 119(1):67-78. PubMed ID: 16386958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN gamma response, even at three years after immunization.
    Kawahara M
    Clin Immunol; 2008 Dec; 129(3):492-8. PubMed ID: 18849196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.
    Kanekiyo M; Matsuo K; Hamatake M; Hamano T; Ohsu T; Matsumoto S; Yamada T; Yamazaki S; Hasegawa A; Yamamoto N; Honda M
    J Virol; 2005 Jul; 79(14):8716-23. PubMed ID: 15994765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
    Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
    Kim BJ; Kim BR; Kook YH; Kim BJ
    Front Immunol; 2018; 9():643. PubMed ID: 29636755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
    Chapman R; Shephard E; Stutz H; Douglass N; Sambandamurthy V; Garcia I; Ryffel B; Jacobs W; Williamson AL
    PLoS One; 2012; 7(3):e32769. PubMed ID: 22479338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of cell-mediated immune response in mice by whole HIV-1 gag in Mycobacterium bovis BCG as a live vaccine candidate.
    Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Sutthent R; Sawanpanyalert P; Warachit P
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):113-22. PubMed ID: 19323043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.
    Chapman R; Stutz H; Jacobs W; Shephard E; Williamson AL
    PLoS One; 2013; 8(8):e71601. PubMed ID: 23977084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
    Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
    Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
    Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
    PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
    Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
    Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.
    Sato H; Jing C; Isshiki M; Matsuo K; Kidokoro M; Takamura S; Zhang X; Ohashi T; Shida H
    Vaccine; 2013 Aug; 31(35):3549-57. PubMed ID: 23731631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles.
    Halsey RJ; Tanzer FL; Meyers A; Pillay S; Lynch A; Shephard E; Williamson AL; Rybicki EP
    Virus Res; 2008 May; 133(2):259-68. PubMed ID: 18329748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines.
    Aldovini A; Young RA
    Nature; 1991 Jun; 351(6326):479-82. PubMed ID: 2046750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.